BOC Sciences provides a wide range of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecule and chiral compounds.
| Product | Description | |
|---|---|---|
| BMS-791325 HCl | BMS-791325 HCl is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. BMS-791325 inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 at 50% inhibitory concentrations (IC50 < 28 nM). In cell culture, BMS-791325 inhibited replication of HCV subgenomic replicons representing genotypes 1a and 1b at 50% effective concentrations (EC50s) of 3 nM and 6 nM, respectively, with similar (3 to 18 nM) values for genotypes 3a, 4a, and 5a. BMS-791325 was found to have distinguishing antiviral, safety, and pharmacokinetic properties that resulted in its selection for clinical evaluation. BMS-791325 is currently under Phase III trials. Synonyms: Beclabuvir hydrochloride; BMS-791325 HCl; BMS 791325 HCl; BMS791325 HCl. Grade:> 98%. CAS No. 958002-36-3. Molecular formula: C36H46ClN5O5S. Mole weight: 696.304. |  |
| BMS-794833 | BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7 nM/15 nM. Synonyms: BMS794833; BMS 794833. Grade: 0.98. CAS No. 1174046-72-0. Molecular formula: C23H15ClF2N4O3. Mole weight: 468.845. | |
| BMS 795311 | BMS 795311 is a potent cholesteryl ester transfer protein (CETP) inhibitor (IC50 = 4 nM in an enzyme-based scintillation proximity assay) that inhibits cholesteryl ester transfer and increases HDL-C levels in vivo. Synonyms: BMS 795311; BMS795311; BMS-795311; N-[(1R)-1-[3-(Cyclopropyloxy)-4-fluorophenyl]-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide. Grade: ≥98% by HPLC. CAS No. 939390-99-5. Molecular formula: C33H23F10NO3. Mole weight: 671.52. | |
| BMS-813160 | BMS-813160 is an effective and selective CCR2/CCR5 antagonist with potential immunomodulatory and anti-tumor activities. It inhibits the activation of CCR2/CCR5 mediated signal transduction pathways, and may inhibit the inflammatory process, angiogenesis, tumor cell migration, tumor cell proliferation and invasion. Synonyms: BMS813160; BMS 813160; BMS 813160-Bio-X. CAS No. 1286279-29-5. Molecular formula: C25H40N8O2. Mole weight: 484.6. | |
| BMS-817378 | BMS-817378 is a potent and selective MET inhibitor with IC50 = 1.7 nM. Synonyms: BMS 817378; BMS817378; 3(4H)-Pyridinecarboxamide, N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-5-(4-fluorophenyl)-4-oxo-1-[(phosphonooxy)methyl]-. CAS No. 1174161-69-3. Molecular formula: C24H18ClF2N4O7P. Mole weight: 578.85. | |
| BMS-833923 | BMS-833923 is an orally bioavailable small-molecule Smo (Smoothened) inhibitor with potential antineoplastic activity. It inhibits the sonic hedgehog (shh) pathway protein Smo, which may result in suppression of shh signaling pathway. Synonyms: BMS 833923; XL139; N-[2-methyl-5-(methylaminomethyl)phenyl]-4-[(4-phenylquinazolin-2-yl)amino]benzamide. Grade: >98%. CAS No. 1059734-66-5. Molecular formula: C30H27N5O. Mole weight: 473.57. | |
| BMS-856 | BMS-856 shows low nanomolar inhibition of 17beta-HSD3 enzymatic activity. It displays inhibition of 17beta-HSD3-mediated cellular conversion of AdT to testosterone and inhibits the 17beta-HSD3-mediated conversion of testosterone necessary to promote AR-dependent transcription. BMS-856 can be used for endocrine therapy of prostate cancer. Uses: Endocrine therapy of prostate cancer. Synonyms: BMS 856; BMS856; UNII-7IQ5DK4G01; 7IQ5DK4G01; 2-((3-chloro-4-hydroxybenzoyl)amino)-N-(2-(2-methoxyphenyl)ethyl)-5-phenoxy-Benzamide. Grade: 98%. CAS No. 863382-83-6. Molecular formula: C29H25ClN2O5. Mole weight: 516.97. | |
| BMS-863233 HCl | BMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor BMS-863233 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. CDC7, a serine-threonine kinase overexpressed in a variety of tumor cell types, plays an essential role in the initiation of DNA replication by activating origins of replication. Check for active clinical trials or closed clinical trials using this agent. Synonyms: BMS-863233; BMS863233; BMS 863233; XL-413; XL413; XL 413. CAS No. 1169562-71-3. Molecular formula: C14H13Cl2N3O2. Mole weight: 289.72. | |
| BMS-890068 | BMS-890068 is an acyclic P1 bi-cyclopropaneacylsulfonamidetripeptide that can be used as hepatitis C virus (HCV) NS3 protease inhibitor. Uses: The treatment of hepatitis c. Synonyms: BMS-890068; BMS 890068; BMS890068. | |
| BMS 903452 | G-protein-coupled receptor 119 agonists can stimulate glucose-dependent insulin release by direct action in the pancreas and promote secretion of the incretin GLP-1 by action in the gastrointestinal tract. BMS-903452 is a selective G-protein-coupled receptor 119 (GRP119) agonist and it is efficacious in both acute and chronic in vivo rodent models of diabetes. Till now, no development was reported for the treatment of Type 2 diabetes mellitus using BMS-903452. Uses: Type 2 diabetes mellitus. Synonyms: BMS-903452; BMS 903452; BMS903452; 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one. Grade: 98%. CAS No. 1339944-47-6. Molecular formula: C21H19Cl2FN4O4S. Mole weight: 513.37. | |
| BMS-905 | BMS905 is an active TLR7 and TLR8 dual inhibitor. It can be used for research of lupus, psoriasis and arthritis. Grade: 98%. CAS No. 2205846-49-5. Molecular formula: C23H29N3. Mole weight: 347.51. | |
| BMS-906024 | BMS-906024, a selective and orally active γ-secretase inhibitor, is a potent inhibitor of pan-Notch receptors with IC50s of 1.6, 0.7, 3.4 and 2.9 nM for Notch-1, -2, -3 and -4 receptors, respectively. It has broad-spectrum antineoplastic activity. Synonyms: (2R,3S)-N1-((S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide; NSC-780812; Butanediamide, N1-((3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluorophenyl)-, (2R,3S)-. Grade: ≥98%. CAS No. 1401066-79-2. Molecular formula: C26H26F6N4O3. Mole weight: 556.50. | |
| BMS-908662 | BMS-908662 is a Raf kinase inhibitor with potential antineoplastic activity. It can specifically inhibit RAF kinases, located downstream from RAS in the RAS/RAF/MEK/ERK kinase signaling pathway, which may result in reduced proliferation of tumor cells. Phase I for the treatment of Colorectal cancer and Malignant melanoma was discontinued. Uses: Colorectal cancer; malignant melanoma. Synonyms: methyl (5-(2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxoisoindolin-1-yl)-1H-benzo[d]imidazol-2-yl)carbamate; BMS908662; BMS-908662; BMS 908662; XL281; XL 281; XL-281. Grade: 98%. CAS No. 870603-16-0. Molecular formula: C24H19ClN4O4. Mole weight: 462.89. | |
| BMS-911543 | BMS-911543 is an orally available JAK inhibitor with selectivity for JAK2. It inhibts JAK2, thereby preventing the JAK/STAT (signal transducer and activator of transcription) signaling cascade, including activation of STAT3. This may lead to an induction of tumor cell apoptosis and a decrease in cellular proliferation. Synonyms: BMS 911543. Grade: >98%. CAS No. 1271022-90-2. Molecular formula: C23H28N8O. Mole weight: 432.532. | |
| BMS-919373 | This active molecular is a Kv1.5 potassium channel inhibitor originated by Bristol-Myers Squibb. Treatment for paroxysmal atrial fibrillation is in Phase II clinical trials. Treatment for Acute coronary syndromes and Atrial fibrillation is in Phase I clinical trials. Synonyms: BMS 919373; BMS919373; 3-Pyridinesulfonamide, 5-[5-phenyl-4-[(2-pyridinylmethyl)amino]-2-quinazolinyl]-; 5-[5-Phenyl-4-[(2-pyridinylmethyl)amino]-2-quinazolinyl]-3-pyridinesulfonamide; 5-[5-phenyl-4-[[(pyridin-2-yl)methyl]amino]quinazolin-2-yl]pyridine-3-sulfonamide. Grade: 98%. CAS No. 1272353-82-8. Molecular formula: C25H20N6O2S. Mole weight: 468.54. | |
| BMS-935177 | BMS-935177 is a potent and selective reversible inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 of 3 nM and demonstrates good kinase selectivity. It is more potent against BTK than other kinase, including the other Tec family kinases (TEC, BMX, ITK, and TXK) over which the compound is between 5- and 67-fold selective. BMS-935177 inhibited calcium flux in human Ramos B cells with IC50 of 27 nM and inhibited CD69 surface expression in peripheral B cells stimulated with anti-IgM and anti-IgG. Synonyms: BMS-935177; BMS935177. Grade: ≥98%. CAS No. 1231889-53-4. Molecular formula: C31H26N4O3. Mole weight: 502.56. | |
| BMS-936559 | Anti-PD-L1 monoclonal antibody BMS-936559 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. Synonyms: MDX1105; BMS936559; MDX 1105; BMS 936559; MDX-1105; BMS-936559; Anti PD L1; PD-L1 inhibitor -Bristol-Myers Squibb. | |
| BMS-955176 | BMS-955176 is the second generation HIV-1 maturation inhibitor. Synonyms: BMS-955176 free base|BMS-955176|UNII-4CA9IAU7RJ|4CA9IAU7RJ|GSK3532795|1392312-45-6|1392312-45-6 (free base)|GSK-3532795|CHEMBL3827379|SCHEMBL12697862|BMS-955176 TFA|EX-A3677|BDBM50450015|BMS955176|DB15193|2097784-79-5|AC-36687|HY-112714|CS-0062829|4((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6. Grade: ≥98% (HPLC). CAS No. 1392312-45-6. Molecular formula: C42H62N2O4S. Mole weight: 691. | |
| BMS-955176 TFA | BMS-955176 TFA is the second generation HIV-1 maturation inhibitor. Synonyms: MS-955176 TFA. CAS No. 2097784-79-5. Molecular formula: C44H63F3N2O6S. Mole weight: 805.05. | |
| BMS-955829 | BMS-955829 shows excellent Metabotropic glutamate receptor 5 (mGluR5) binding affinity, low glutamate fold shift, and high selectivity for the mGluR5 subtype. BMS-955829 is a potent mGluR5 Positive allosteric modulator (PAM) (EC50 = 2.6 ± 1.0 nM; n=6), devoid of inherent mGluR5 agonist activity (EC50 > 30μM). It may become a new drug candidate for the treatment of schizophrenia. Uses: Schizophrenia. Synonyms: BMS-955829; BMS 955829; BMS955829. (4R,5R)-5-(2,5-difluorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one. Grade: 98%. CAS No. 1375751-08-8. Molecular formula: C22H14F2N2O2. Mole weight: 376.36. | |
| BMS 961 | BMS 961 is a potent and selective retinoic acid receptor gamma (RARγ) agonist with an IC50 value of 30 nM. Synonyms: BMS961; BMS-961; 3-Fluoro-4-[[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino]-benzoic acid; Benzoic acid, 3-fluoro-4-[[2-hydroxy-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)acetyl]amino]-. Grade: ≥97% by HPLC. CAS No. 185629-22-5. Molecular formula: C23H26FNO4. Mole weight: 399.45. | |
| BMS-983970 | BMS-983970 is an oral pan-Notch inhibitor for the treatment of cancer. Synonyms: BMS-983970; BMS 983970; BMS983970. Grade: >98%. CAS No. 1584713-87-0. Molecular formula: C26H26F4N4O3. Mole weight: 518.5. | |
| BMS-984923 | BMS-984923 is a potent mGluR5 silent allosteric modulator (SAM) with exquisite binding affinity (Ki = 0.6 nM). BMS-984923 exhibits good oral bioavailability and BBB penetration. BMS-984923 potently inhibits the PrPC-mGluR5 interaction and prevents pathological Aβo signaling without affecting physiological glutamate signaling. Synonyms: BMS984923; 2-Oxazolidinone, 5-(2-chlorophenyl)-4-(5-(2-phenylethynyl)-3-pyridinyl)-, (4R,5R)-. CAS No. 1375752-78-5. Molecular formula: C22H15ClN2O2. Mole weight: 374.82. | |
| BMS 986020 | BMS 986020 is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist with an IC50 value less than 300 nM for human LPA1 expressing CHO cells. It inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS 986020 is used for the treatment of idiopathic pulmonary fibrosis (IPF). Synonyms: BMS-986020; BMS986020. Grade: ≥98%. CAS No. 1257213-50-5. Molecular formula: C29H26N2O5. Mole weight: 482.5. | |
| BMS-986020 sodium | BMS-986020 sodium is a high affinity antagonist of lysophosphatidic acid receptor 1 (LPA1) that inhibits bile acids and phospholipid transporters with IC50s of 4.8, 6.2 and 7.5 μM against BSEP, MRP4 and MDR3, respectively. It has the potential to treat idiopathic pulmonary fibrosis (IPF). Synonyms: Sodium 1-{4'-[3-methyl-4-({[(1R)-1-phenylethoxy]carbonyl}amino)-1,2-oxazol-5-yl]-4-biphenylyl}cyclopropanecarboxylate; Cyclopropanecarboxylic acid, 1-[4'-[3-methyl-4-[[[(1R)-1-phenylethoxy]carbonyl]amino]-5-isoxazolyl][1,1'-biphenyl]-4-yl]-, sodium salt (1:1); Sodium (R)-1-(4'-(3-methyl-4-(((1-phenylethoxy)carbonyl)amino)isoxazol-5-yl)-[1,1'-biphenyl]-4-yl)cyclopropane-1-carboxylate. Grade: ≥95%. CAS No. 1380650-53-2. Molecular formula: C29H25N2NaO5. Mole weight: 504.51. | |
| BMS-986120 | BMS-986120, an imidazoles derivative, has been found to be a PAR4 antagonist that could probably be effective against thrombus propagation and pathological vascular occlusion. It was just completed a Phase I trail in in Thrombosis. Synonyms: BMS-986120; BMS 986120; BMS986120; 4-(4-(((6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)-5-methylthiazol-2-yl)morpholine. Grade: 98%. CAS No. 1478712-37-6. Molecular formula: C23H23N5O5S2. Mole weight: 513.59. | |
| BMS-986121 | BMS-986121 is an allosteric modulator (PAM) of the μ opioid receptor extracted from patent WO2014107344. CAS No. 313671-26-0. Molecular formula: C15H9Cl2N3O2S. Mole weight: 366.22. | |
| BMS 986122 | BMS 986122 is a positive allosteric modulator of the μ-Opioid receptor. It significantly increases the inhibition of forskolin-stimulated adenylyl cyclase activity produced by an EC10 (30 pM) concentration of endomorphin-I in CHO-μ cells. BMS 986122 potentiates endomorphin 1-induced inhibition of forskolin-stimulated adenylyl cyclase activity in CHO cells expressing human recombinant μ-opioid receptors with EC50 of 8.9 μM. It also enhances [35S]GTPγ binding stimulated by the μ-opioid agonist DAMGO by 7- and 4.5-fold in C6μ glioma cell membranes. Synonyms: BMS-986122; BMS986122; 2-(3-bromo-4-methoxyphenyl)-3-[(4-chlorophenyl)sulfonyl]-thiazolidine. Grade: ≥98%. CAS No. 313669-88-4. Molecular formula: C16H15BrClNO3S2. Mole weight: 448.8. | |
| BMS-986141 | BMS-986141 is a potential medication under the clinical trial that evaluates the pharmacokinetics of BMS-986141 in participants with hepatic impairment compared to healthy participants. Synonyms: Unii-W530irz40G. CAS No. 1478711-48-6. Molecular formula: C27H23N5O5S2. Mole weight: 561.6. | |
| BMS-986142 | Bruton's tyrosine kinase (BTK) is a nonreceptor tyrosine kinase. It is a member of the Tec family of kinases. BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling. BMS-986142 is a potent, selective and reversible BTK inhibitor with IC50 of 0.5 nM. It potently inhibits BCR-stimulated expression of CD69 on B cells in human whole blood with IC50 of 90 nM. Synonyms: BMS-986142; BMS986142. Grade: ≥98%. CAS No. 1643368-58-4. Molecular formula: C32H30F2N4O4. Mole weight: 572.60. | |
| BMS-986143 | BMS-986143 is an orally active, reversible BTK inhibitor with an IC50 of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1 and ITK with IC50s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM, 19 nM and 21 nM, respectively. BMS-986143 can be used in the study of autoimmune diseases. Synonyms: 3-chloro-4-(3-(5-chloro-1,3-dioxo-1H-pyrido[1,2-c]pyrimidin-2(3H)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9H-carbazole-1-carboxamide; 9H-Carbazole-1-carboxamide, 3-chloro-4-[3-(5-chloro-1,3-dioxo-1H-pyrido[1,2-c]pyrimidin-2(3H)-yl)-2-methylphenyl]-7-(1-hydroxy-1-methylethyl)-. Grade: ≥98%. CAS No. 1643372-95-5. Molecular formula: C31H24Cl2N4O4. Mole weight: 587.45. | |
| BMS-986158 | BMS-986158 is an inhibitor of the bromodomain and extra-terminal (BET) proteins with potential antineoplastic activity. Synonyms: 2-[3-(3,5-dimethyltriazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol; BMS-986158; BMS 986158; BMS986158. CAS No. 1800340-40-2. Molecular formula: C30H33N5O2. Mole weight: 495.62. | |
| BMS-986165 | BMS-986165 is a potent and selective TYK2 inhibitor that blocks signal transduction of IL-23, IL-12, and type I IFNs. It binds to the Tyk2 pseudokinase domain (Ki = 0.02 nM), and is highly selective against a panel of 265 kinases and pseudokinases. BMS-986165 is under a phase III clinical trial for the treatment of Psoriasis. Synonyms: Deucravacitinib; BMS 986165; BMS986165; Tyk2-IN-4; Sotyktu. Grade: 98%. CAS No. 1609392-27-9. Molecular formula: C20H19D3N8O3. Mole weight: 425.47. | |
| BMS 986187 | BMS 986187 is a potent and selective δ-opioid receptor positive allosteric modulator (EC50 = 30 nM) exhibiting 100-fold selectivity for δ over μ-opioid receptor. Synonyms: BMS 986187; BMS986187; BMS-986187; 3,4,5,6,7,9-Hexahydro-3,3,6,6-tetramethyl-9-[4-[(2-methylphenyl)methoxy]phenyl]-1H-xanthene-1,8(2H)-dione. Grade: ≥98% by HPLC. CAS No. 684238-37-7. Molecular formula: C31H34O4. Mole weight: 470.61. | |
| BMS 986188 | BMS 986188 is a novel potent and selective positive allosteric modulator of the delta-opioid receptor. It is selective for δ- over μ-opioid receptors with EC50 of 10 μM in the presence of leu-enkephalin and the μ-opioid receptor agonist endomorphin 1, respectively. Synonyms: MS-986188; BMS 986188. Grade: ≥98%. CAS No. 1776115-10-6. Molecular formula: C30H31BrO4. Mole weight: 535.5. | |
| BMS-986195 | BMS-986195 is a Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 0.1 nM. Synonyms: Branebrutinib; BMS 986195; BMS986195. Grade: ≥98% by HPLC. CAS No. 1912445-55-6. Molecular formula: C20H23FN4O2. Mole weight: 370.42. | |
| BMS986195 R-isomer | An R isomer of BMS-986195, a potent and selective inhibitor of Bruton's tyrosine kinase (BTK). Synonyms: (R)-4-(3-(But-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; (R)-Branebrutinib; (R)-BMS-986195. CAS No. 1912445-70-5. Molecular formula: C20H23FN4O2. Mole weight: 370.42. | |
| BMS-986205 | BMS-986205 is a selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. It is undergoing a phase I/II clinical trial for the bladder and cervical cancer therapy in combination with nivolumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody. Uses: Drug combination with nivolumab. Synonyms: BMS-986205; BMS 986205; BMS986205; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide. CAS No. 1923833-60-6. Molecular formula: C24H24ClFN2O. Mole weight: 410.917. | |
| BMS-986242 | BMS-986242 is a potent and selective inhibitor of Indoleamine 2,3-dioxygenase 1 (IDO1), a heme-containing dioxygenase enzyme implicated in cancer immune response. BMS-986242 has been developed for the treatment of a variety of cancers including metastatic melanoma and renal cell carcinoma. Synonyms: BMS 986242; BMS986242. Grade: 98% by HPLC. CAS No. 1923844-48-7. Molecular formula: C24H24ClFN2O. Mole weight: 410.9. | |
| BMS-986278 | BMS-986278 is a potent antagonist of lysophosphatidic acid receptor 1 (LPA1), with a human LPA1 Kb of 6.9 nM. Synonyms: (1S,3S)-3-((2-Methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid; Cyclohexanecarboxylic acid, 3-((2-methyl-6-(1-methyl-5-((((methylpropylamino)carbonyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)-3-pyridinyl)oxy)-, (1S,3S)-. Grade: ≥95%. CAS No. 2170126-74-4. Molecular formula: C22H31N5O5. Mole weight: 445.51. | |
| BMS-986299 | BMS-986299 is a first-in-class NLRP3 inflammasome agonist with EC50 of 1.28 μM. BMS-986299 is usdergoing a clinical trial alone and in combination with Nivolumab and Ipilimumab for the treatment of advanced solid tumors. Synonyms: BMS 986299; BMS986299. CAS No. 2242952-69-6. Molecular formula: C18H19N7O. Mole weight: 349.39. | |
| BMS CCR2 22 | BMS CCR2 22 is a potent CCR2 antagonist. Synonyms: N-[2-[[2-[(4-methylsulfanylbenzoyl)amino]cyclohexyl]amino]-2-oxoethyl]-2-(propan-2-ylcarbamoylamino)-5-(trifluoromethyl)benzamide. CAS No. 445479-97-0. Molecular formula: C28H34F3N5O4S. Mole weight: 593.66. | |
| BMS-P5 | BMS-P5 is a novel peptidylarginine deiminase 4 (PAD4) inhibitor with pIC50 values in the range of 5-7.5. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model. Synonyms: BM P5; BMSP5; BMSP-5; BMSP 5; BMS-P5 HCl. CAS No. 1549811-36-0. Molecular formula: C27H33ClN6O2. Mole weight: 509.04. | |
| BMS-P5 free base | BMS-P5 is a novel peptidylarginine deiminase 4 (PAD4) inhibitor with pIC50 values in the range of 5-7.5. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model. Synonyms: [(2S,5R)-5-amino-2-methyl-1-piperidinyl][2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-methanone. Grade: 99%. CAS No. 1550371-22-6. Molecular formula: C27H32N6O2. Mole weight: 472.59. | |
| BMT-1438 | BMT-1438 is a selective inhibitor of Janus kinase (JAK) family with less side effcts which is potentially used for the treatment of rheumatoid arthritis and other autoimmune diseases. It has a preference for JAK1 and JAK3. BMT-1438 showed excellent effect both in vitro and in a collagen-induced arthritis mouse model. Uses: The potential treatment of rheumatoid arthritis and other autoimmune diseases. Synonyms: BMT-1438; BMT 1438; BMT1438. | |
| BMT-145027 | BMT-145027 is a potent mGluR5 PAM without inherent agonist activity with an EC50 of 47 nM. BMT-145027 is a non-MPEP site PAM to demonstrate in vivo efficacy. Synonyms: BMT-145027; BMT 145027; BMT145027; 3-[4-chloro-3-(trifluoromethyl)phenyl]-4-cyclopropyl-6-phenyl-2H-pyrazolo[3,4-b]pyridine-5-carbonitrile. CAS No. 2018282-44-3. Molecular formula: C23H14ClF3N4. Mole weight: 438.83. | |
| BMVC | BMVC is the first fluorescent probe designed to detect G-quadruplexes (G4s) in vivo. BMVC is a potent G-quadruplex (G4) stabilizer and a selective telomerase inhibitor. Grade: 98%. CAS No. 627810-06-4. Molecular formula: C28H25I2N3. Mole weight: 657.33. | |
| BMVC2 | BMVC2, a bisubstituted carbazole derivative of BMVC, is a G-quadruplex (G4) stabilizer. Synonyms: o-BMVC; 2,2'-((9H-Carbazole-3,6-diyl)bis(ethene-2,1-diyl))bis(1-methylpyridin-1-ium) iodide; 2,2'-[9H-Carbazole-3,6-diyldi(E)-2,1-ethenediyl]bis(1-methylpyridinium) diiodide. Grade: ≥95%. CAS No. 850559-51-2. Molecular formula: C28H25I2N3. Mole weight: 657.33. | |
| BMX-IN-1 | BMX-IN-1 selectively and irreversibly inhibits BMX (IC50=8nM) that is significant for ischemia-mediated arteriogenesis and lymphangiogenesis regulation. It also inhibits the proliferation of RV-1 (GI50s=2.54μM), DU-145 (GI50s=4.38μM), PC-3 (GI50s=5.37nM). Synonyms: N-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamideBMX-IN-1; BMX-IN1; BMX-IN 1.1431525-23-3GTPL9269SCHEMBL17052523BDBM102620CS-1295; HY-80002; W-6056; CS 1295; HY 80002; W 6056; CS1295; HY80002; W6056Example 1-14 [ WO2014063054]N-[5-[9-[4-(methanesulfonamido)phenyl]. CAS No. 1431525-23-3. Molecular formula: C29H24N4O4S. Mole weight: 524.59. | |
| BMY 14802 hydrochloride | BMY 14802 hydrochloride is a potent sigma receptor antagonist (IC50 = 112 nM) with weak affinity for 5-HT1A and α1 receptors. BMY 14802 is potentially used as an atypical antipsychotic agent for schizophrenia treatment. Uses: Potential atypical antipsychotic agent. Synonyms: BMY 14802 hydrochloride; BMS-181100 hydrochloride; BMY14802 hydrochloride; BMS181100 hydrochloride; BMY-14802 hydrochloride; BMS 181100 hydrochloride; BMY 14802 HCl; α-(4-Fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol hydrochloride. Grade: ≥98% by HPLC. CAS No. 105565-55-7. Molecular formula: C18H22F2N4O.HCl. Mole weight: 384.86. | |
| BMY-25271 | BMY-25271 is an antagonist of histamine H2 receptor. Synonyms: N-[2-[[[5-[(Dimethylamino)methyl]furan-2-yl]methyl]thio]ethyl]-1,2,5-thiadiazole-3,4-diamine 1-oxide; 1,2,5-Thiadiazole-3,4-diamine, N3-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-, 1-oxide. Grade: ≥95%. CAS No. 78441-82-4. Molecular formula: C12H19N5O2S2. Mole weight: 329.44. | |
| Bmy 42393 | BMY-42393 is a selective platelet aggregation inhibitor. It is also a prostacyclin partial agonist that inhibited ADP, collagen and thrombin-induced platelet aggregation with IC50 value range from 0.3 to 2.0 mM. BMY-42393 can stimulate platelet adenylate cyclase with EC50 value of 25 nM. BMY 42393 can also inhibit thrombin-induced elevation of intracellular free calcium. Research for the treatment of Hyperlipidaemia was discontinued. Uses: Hyperlipidaemia. Synonyms: BMY-42393; BMY 42393; BMY42393. SCHEMBL675089; AC1L304B; CHEMBL117835; 2-[3-[2-(4,5-diphenyl-1,3-oxazol-2-yl)ethyl]phenoxy]acetic acid. Grade: 98%. CAS No. 136451-58-6. Molecular formula: C25H21NO4. Mole weight: 399.45. | |
| BMY-43748 | BMY-43748 is an antibacterial compound with great in vitro and in vivo antibacterial activity. CAS No. 132195-65-4. Molecular formula: C20H17F3N4O3. Mole weight: 418.37. | |
| BMY 45778 | BMY 45778 is a non-prostanoid prostacyclin mimetic that acts as a partial agonist of IP1 prostacyclin receptors. It inhibits platelet aggregation in vitro (IC50 = 27-35 nM). Synonyms: BMY 45778; BMY45778; BMY-45778. [3-(4,5-Diphenyl[2,4'-bioxazol]-5'-yl)phenoxy]acetic acid. Grade: ≥99% by HPLC. CAS No. 152575-66-1. Molecular formula: C26H18N2O5. Mole weight: 438.44. | |
| BMY 7378 | BMY 7378 is a multi-targeted inhibitor of α2C-adrenoceptor and α1D-adrenoceptor with pKi of 6.54 and 8.2, respectively, and acts as a mixed agonist and antagonist for 5-HT1A receptor with pKi of 8.3. Uses: Adrenergic alpha-antagonists. Synonyms: BMY7378; BMY-7378; 1,1-Cyclopentanediacetimide, N-(2-(4-(o-methoxyphenyl)-1-piperazinyl)ethyl)-, dihydrochloride; N-(2-(4-(o-Methoxyphenyl)-1-piperazinyl)ethyl)-1,1-cyclopentanediacetimide dihydrochloride. Grade: >98%. CAS No. 21102-95-4. Molecular formula: C22H33Cl2N3O3. Mole weight: 458.42. | |
| BN80933 | BN80933 is a dual inhibitor of lipid peroxidation (IC50 = 0.29 μM) and neuronal nitric oxide synthase (nNOS) (Ki = 0.92 μM). Synonyms: (S)-N-(4-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-carbonyl)piperazin-1-yl)phenyl)thiophene-2-carboximidamide. Grade: 98%. CAS No. 214348-10-4. Molecular formula: C29H34N4O3S. Mole weight: 518.67. | |
| BN 82002 | BN 82002, also known as CDC25 Phosphatase Inhibitor I, is a cell-permeable ortho-hydroxybenzylamino compound that displays anti-tumor properties. Synonyms: BN-82002; BN82002; Phenol, 4-(dimethylamino)-2-methoxy-6-((methyl(2-(4-nitrophenyl)ethyl)amino)methyl)-. CAS No. 396073-89-5. Molecular formula: C19H25N3O4. Mole weight: 359.42. | |
| b-Naphthyl-b-maltotrioside | b-Naphthyl-b-maltotrioside is a highly esteemed enzymatic substrate extensively employed in the realm of biomedical science, encompassing a consequential instrument empowering the analysis of lactase insufficiency and enzyme efficacy. Synonyms: Naphthyl O-α-D-glucopyranosyl-(1→4)-O-α-D-glucopyranosyl-(1→4)-β-D-glucopyranoside; Naphthyl β-maltotrioside; (2R,3R,4S,5S,6R)-2-(((2R,3S,4R,5R,6R)-6-(((2R,3S,4R,5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-(naphthalen-2-yloxy)tetrahydro-2H-pyran-3-yl)oxy)-4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol. Molecular formula: C28H38O16. Mole weight: 630.59. | |
| BNC-105 | BNC105 is a novel compound being developed by Bionomics as a Vascular Disrupting Agent (VDA) for treatment of cancer. VDAs are drugs that disrupt the blood vessels that nourish tumours. BNC105 acts as a tubulin polymerization inhibitor and displays 80-fold higher potency against endothelial cells than that of CA4P. CA4P is a VDA currently under evaluation in phase III clinical trials. BNC105 is more potent and offers a wider therapeutic window. CA4P produces 90% vascular disruption at its no observed adverse event level (NOAEL), whereas BNC105 causes 95% vascular disruption at 1/8th of its NOAEL. Tissue distribution analysis of BNC105 in tumor-bearing mice showed that while the drug is cleared from all tissues 24 hours after administration, it is still present at high concentrations within the solid tumor mass. Furthermore, BNC105 treatment causes tumor regressions with complete tumor clearance in 20% of treated animals. Synonyms: BCN-105; BCN105; BCN 105. CAS No. 945771-74-4. Molecular formula: C20H20O7. Mole weight: 372.373. | |
| BNC105P | BNC105P is a benzofuran-based vascular disrupting agent (VDA) prodrug with potential anti-vascular and antineoplastic activities. Upon administration vascular disrupting agent BNC105P, the disodium phosphate ester of BNC105, is rapidly converted to BNC105; in activated endothelial cells, BNC105 binds to tubulin and inhibits its polymerization, which may result in a blockage of mitotic spindle formation, cell cycle arrest, and disruption of the tumor vasculature. Hypoxic conditions ensue, depriving tumor cells of nutrients and resulting in tumor cell apoptosis. In addition to its VDA activity, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization. BNC105 is not a substrate for the multidrug-resistance P-glycoprotein (Pgp) transporter. Check for active clinical trials or closed clinical trials using this agent. Synonyms: BNC105P; BNC 105P; BNC-105P. CAS No. 945771-96-0. Molecular formula: C20H19Na2O10P. Mole weight: 496.32. | |
| BNC375 | BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs. Synonyms: 4-((1R,3R)-3-(((5-chloro-2-methoxyphenyl)amino)methyl)-2,2-dimethylcyclopropyl)benzenesulfonamide. Grade: 99%. CAS No. 1557240-80-8. Molecular formula: C19H22ClN2O3S. Mole weight: 394.91. | |
| b-Nicotinamide adenine dinucleotide 3'-phosphate sodium salt hydrate | b-Nicotinamide adenine dinucleotide 3'-phosphate sodium salt hydrate, a pivotal coenzyme in the biomedical arena, exhibits its significance as a redox carrier and electron donor in diverse metabolic reactions. With its application in the amelioration of oxidative stress-induced ailments, including cardiovascular diseases and neurological disorders, this product assumes a critical function in cellular energy synthesis and the preservation of cellular well-being. Imbibed with indispensability, it perpetuates the vitality of the biotic system. Molecular formula: C21H27N7O17P3·xNa·yH20. Mole weight: 742.40 (anhydrous free acid). | |
| b-Nicotinamide adenine dinucleotide phosphate disodium salt | b-Nicotinamide adenine dinucleotide phosphate disodium salt, an indispensable coenzyme, demonstrates pivotal significance in diverse biochemical reactions. This coveted compound finds extensive employment within the biomedical domain, catering to research and therapeutic exigencies. Its multifarious application encompasses the meticulous scrutiny of cellular metabolism, DNA repair mechanisms and intricate redox reactions. Moreover, it assumes a vital role in alleviating maladies associated with oxidative stress, namely neurodegenerative disorders and cardiovascular ailments. Molecular formula: C21H26N7O19P3·2Na. Mole weight: 819.37. | |
| b-Nicotinamide adenine dinucleotide phosphate hydrate | Coenzyme and regenerating electron donor in catabolic processes. Synonyms: b-NADP; Coenzyme II. Molecular formula: C21H28N7O17P3·xH2O. Mole weight: 743.41 (anydrous basis). | |
| b-Nicotinamide adenine dinucleotide phosphate potassium salt hydrate | b-Nicotinamide adenine dinucleotide phosphate potassium salt hydrate exemplifies an essential coenzyme that assumes a pivotal function in diverse biochemical reactions. This compound emerges as uniquely advantageous towards interrogating cellular metabolism, enzyme kinetics and redox reactions. Synonyms: coenzyme II; b-NADP-K; Triphosphopyridine nucleotide potassium salt; TPN; [5-(6-aminopurin-9-yl)-3-hydroxy-4-(oxyphosphinyloxyphosphinyl)oxolan-2-yl]met hyl{[5-(3-carbamoylpyridyl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxyphosphoryl)hydrogen phosphate,potassium salt; Beta-nadp potassium salt; Nadp monopotassium salt. Grade: ≥ 90%. CAS No. 68141-45-7. Molecular formula: C21H27KN7O17P3. Mole weight: 781.50. | |
| b-Nicotinamide riboside chloride | b-Nicotinamide riboside chloride is an essential biomedical innovation, emerging as a distinguished precursor of the esteemed coenzyme, nicotinamide adenine dinucleotide (NAD+). At the helm of cellular energy metabolism, NAD+ assuming an indispensable role and remains entwined in the intricate web of age-related ailments. Synonyms: 3-(Aminocarbonyl)-1-a-D-ribofuranosyl-pyridinium chloride; Nicotinamide riboside (chloride); 3-Carbamoyl-1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyridin-1-ium chloride; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide chloride. Grade: > 90%. CAS No. 23111-00-4. Molecular formula: C11H15N2O5·Cl. Mole weight: 290.70. | |
| Bnlm | Bnlm is a Grp94 selective inhibitors. Grade: >98%. CAS No. 1380296-82-1. Molecular formula: C20H19ClN2O2. Mole weight: 386.83. | |
| BNM-III-170 | BNM-III-170 can inhibit HIV-1 virus entry into target cells. Synonyms: N1-(4-Chloro-3-fluorophenyl)-N2-((1R,2R)-2-(guanidinomethyl)-5-((methylamino)methyl)-2,3-dihydro-1H-inden-1-yl)oxalamide bis(2,2,2-trifluoroacetate). Grade: ≥95%. CAS No. 1859189-55-1. Molecular formula: C25H26ClF7N6O6. Mole weight: 674.95. | |
| BNTX maleate | BNTX maleate is a selective DOR (δ1 opioid receptor) antagonist with Ki of 0.83 nM (rat). It inhibits neurogenic ion transport in porcine ileal mucosa. Synonyms: 7-Benzylidenenaltrexone maleate. Grade: ≥99%. CAS No. 864461-31-4. Molecular formula: C27H27NO4·C4H4O4. Mole weight: 545.59. | |
| BO-264 | BO-264 is a highly effective and orally active transforming acidic coiled coil 3 (TACC3) inhibitor with IC50 of 188 nM and Kd of 1.5 nM. It has broad-spectrum anti-tumor activity. Synonyms: BO264; BO 264; N-[3-(4-methoxyphenyl)-1,2-oxazol-5-yl]-2-(morpholin-4-yl)pyrimidin-4-amine. Grade: 98%. CAS No. 2408648-20-2. Molecular formula: C18H19N5O3. Mole weight: 353.38. | |
Our database is helping our users find suppliers everyday.
